Cargando…

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy

We investigated the association of time to prostate-specific antigen nadir (TTPN) and logarithm of prostate-specific antigen velocity after progression Log(PSAVAP) in metastatic prostate cancer with prior primary androgen deprivation therapy (ADT). All metastatic prostate cancer patients treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, Jeremy YC, Tsu, James HL, Yuen, Steffi KK, Chiu, Peter KF, Chan, Samson YS, Wong, Ka-Wing, Ho, Kwan-Lun, Hou, Simon SM, Ng, Chi-Fai, Yiu, Ming-Kwong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227682/
https://www.ncbi.nlm.nih.gov/pubmed/26585698
http://dx.doi.org/10.4103/1008-682X.164921
_version_ 1782493852049866752
author Teoh, Jeremy YC
Tsu, James HL
Yuen, Steffi KK
Chiu, Peter KF
Chan, Samson YS
Wong, Ka-Wing
Ho, Kwan-Lun
Hou, Simon SM
Ng, Chi-Fai
Yiu, Ming-Kwong
author_facet Teoh, Jeremy YC
Tsu, James HL
Yuen, Steffi KK
Chiu, Peter KF
Chan, Samson YS
Wong, Ka-Wing
Ho, Kwan-Lun
Hou, Simon SM
Ng, Chi-Fai
Yiu, Ming-Kwong
author_sort Teoh, Jeremy YC
collection PubMed
description We investigated the association of time to prostate-specific antigen nadir (TTPN) and logarithm of prostate-specific antigen velocity after progression Log(PSAVAP) in metastatic prostate cancer with prior primary androgen deprivation therapy (ADT). All metastatic prostate cancer patients treated with primary ADT from 2000 to 2009 were reviewed. Patients who developed disease progression were included in the subsequent analyses. Patients were categorized into three groups according to their TTPN: TTPN of <3 months, 3–17 months, and >17 months. We compared the Log(PSAVAP) between the different TTPN groups using Mann–Whitney U-test and Kruskal–Wallis test. Further multiple linear regression analyses on Log(PSAVAP) were performed to adjust for other potential confounding factors. Among 419 patients who were treated with primary ADT, 306 patients developed disease progression with a median follow-up of 28 months. Longer TTPN was associated with lower Log(PSAVAP) (P = 0.008) within all subgroup analyses (TTPN of <3 vs 3–17 months, P = 0.020; TTPN of 3–17 vs >17 months, P = 0.009; and TTPN of <3 vs >17 months, P = 0.001). Upon multiple linear regression analyses, baseline PSA (regression coefficient 0.001, P = 0.045), PSA nadir (regression coefficient 0.002, P = 0.040), and TTPN (regression coefficient −0.030, P = 0.001) were the three factors that were significantly associated with Log(PSAVAP). In conclusion, a longer TTPN was associated with lower Log(PSAVAP) in metastatic prostate cancer patients following primary ADT. TTPN cut-offs at 3 months and 17 months appeared to have prognostic significance in predicting Log(PSAVAP). TTPN may serve as a good prognostic indicator in deciding the treatment strategy in patients with disease progression.
format Online
Article
Text
id pubmed-5227682
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-52276822017-02-03 Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy Teoh, Jeremy YC Tsu, James HL Yuen, Steffi KK Chiu, Peter KF Chan, Samson YS Wong, Ka-Wing Ho, Kwan-Lun Hou, Simon SM Ng, Chi-Fai Yiu, Ming-Kwong Asian J Androl Original Article We investigated the association of time to prostate-specific antigen nadir (TTPN) and logarithm of prostate-specific antigen velocity after progression Log(PSAVAP) in metastatic prostate cancer with prior primary androgen deprivation therapy (ADT). All metastatic prostate cancer patients treated with primary ADT from 2000 to 2009 were reviewed. Patients who developed disease progression were included in the subsequent analyses. Patients were categorized into three groups according to their TTPN: TTPN of <3 months, 3–17 months, and >17 months. We compared the Log(PSAVAP) between the different TTPN groups using Mann–Whitney U-test and Kruskal–Wallis test. Further multiple linear regression analyses on Log(PSAVAP) were performed to adjust for other potential confounding factors. Among 419 patients who were treated with primary ADT, 306 patients developed disease progression with a median follow-up of 28 months. Longer TTPN was associated with lower Log(PSAVAP) (P = 0.008) within all subgroup analyses (TTPN of <3 vs 3–17 months, P = 0.020; TTPN of 3–17 vs >17 months, P = 0.009; and TTPN of <3 vs >17 months, P = 0.001). Upon multiple linear regression analyses, baseline PSA (regression coefficient 0.001, P = 0.045), PSA nadir (regression coefficient 0.002, P = 0.040), and TTPN (regression coefficient −0.030, P = 0.001) were the three factors that were significantly associated with Log(PSAVAP). In conclusion, a longer TTPN was associated with lower Log(PSAVAP) in metastatic prostate cancer patients following primary ADT. TTPN cut-offs at 3 months and 17 months appeared to have prognostic significance in predicting Log(PSAVAP). TTPN may serve as a good prognostic indicator in deciding the treatment strategy in patients with disease progression. Medknow Publications & Media Pvt Ltd 2017 2015-11-10 /pmc/articles/PMC5227682/ /pubmed/26585698 http://dx.doi.org/10.4103/1008-682X.164921 Text en Copyright: © 2017 AJA, SIMM & SJTU http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Teoh, Jeremy YC
Tsu, James HL
Yuen, Steffi KK
Chiu, Peter KF
Chan, Samson YS
Wong, Ka-Wing
Ho, Kwan-Lun
Hou, Simon SM
Ng, Chi-Fai
Yiu, Ming-Kwong
Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title_full Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title_fullStr Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title_full_unstemmed Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title_short Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
title_sort association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227682/
https://www.ncbi.nlm.nih.gov/pubmed/26585698
http://dx.doi.org/10.4103/1008-682X.164921
work_keys_str_mv AT teohjeremyyc associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT tsujameshl associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT yuensteffikk associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT chiupeterkf associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT chansamsonys associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT wongkawing associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT hokwanlun associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT housimonsm associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT ngchifai associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy
AT yiumingkwong associationoftimetoprostatespecificantigennadirandlogarithmofprostatespecificantigenvelocityafterprogressioninmetastaticprostatecancerwithpriorprimaryandrogendeprivationtherapy